Actively Recruiting

Phase Not Applicable
Age: 55Years - 79Years
All Genders
NCT05495087

IHT for Mild Cognitive Impairment

Led by University of North Texas Health Science Center · Updated on 2026-04-29

66

Participants Needed

1

Research Sites

165 weeks

Total Duration

On this page

Sponsors

U

University of North Texas Health Science Center

Lead Sponsor

U

University of Texas Southwestern Medical Center

Collaborating Sponsor

AI-Summary

What this Trial Is About

This phase I clinical trial will examine the safety and efficacy of intermittent hypoxia training (IHT) for up to 12 weeks to treat subjects with mild cognitive impairment (MCI).

CONDITIONS

Official Title

IHT for Mild Cognitive Impairment

Who Can Participate

Age: 55Years - 79Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult men and women ages 55 to 79 years old who have been diagnosed with MCI.
  • Willing to be assigned to either treatment or sham-treatment control group.
  • Able to attend multiple lab visits for assessments.
  • Able to breathe moderately low-oxygen air via an air-cushioned disposable facemask.
  • Have controlled and stable chronic conditions for at least 6 months, such as hypertension, coronary artery disease, diabetes, metabolic disease, chronic bronchitis, degenerative osteoporosis or arthritis, or other aging-related chronic conditions.
  • Must be free of depression at enrollment.
  • Have arterial oxygen saturation of 95% or higher and cerebral tissue oxygenation of 50% or higher at rest.
  • Women must be post-menopausal.
Not Eligible

You will not qualify if you...

  • Unwilling to sign written consent for this double-blinded placebo-controlled phase I trial.
  • Diagnosed with Alzheimer's disease dementia or have impaired independent daily functioning; MMSE less than 20 and/or Clinical Dementia Rating of 1 or higher.
  • Unable to visit the lab independently.
  • Claustrophobic to facemask or hyper-reactive to hypoxia exposure.
  • Expecting major surgery or transplant.
  • Have uncontrolled chronic conditions including blood pressure over 150/90 mmHg despite medications, diabetes, chronic renal failure, recurrent chest pain, seizures or epilepsy, moderate to severe carotid artery stenosis or calcification, brain aneurysm, uncontrolled allergic rhinitis, pulmonary fibrosis, emphysema, cancer, infectious disease, atrial fibrillation, regular premature ventricular contractions, myocardial ischemia or infarction, or certain heart blockades.
  • Have severe head injury, traumatic brain injury, or stroke.
  • Currently diagnosed with depression.
  • Currently have COVID-19.
  • Have metallic implants or are claustrophobic.
  • Currently participating in any interventional study or previously exposed to hypoxia (living above 5000 ft for more than two months in past 3 years or prior hypoxia training study).

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of North Texas Health Science Center

Fort Worth, Texas, United States, 76107

Actively Recruiting

Loading map...

Research Team

X

Xiangrong Shi, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here